Nasdaq confirms Alaunos has regained stockholders' equity compliance, cancels hearingOct 23Exchange listingAlaunos Therapeutics, Inc.Updated
Alaunos acquires Velaris Therapeutics, lines up $350 million PIPE financingOct 13M&AAlaunos Therapeutics, Inc.Liquidia Corp
Alaunos Therapeutics' indibulin breast cancer trial terminated after Phase 1 onlyOct 2Trial updateAlaunos Therapeutics, Inc.
Phase 1b indibulin-capecitabine trial ended early after no dose-limiting toxicity seenSep 30Trial updateAlaunos Therapeutics, Inc.capecitabine
Alaunos Therapeutics trial of darinaparsin in blood cancers ended early, record updatedSep 30Trial updateAlaunos Therapeutics, Inc.
Alaunos Therapeutics trial of darinaparsin in liver cancer ends after first stageSep 30Trial updateAlaunos Therapeutics, Inc.
Alaunos Therapeutics trial of palifosfamide plus doxorubicin in sarcoma ended early after interim anSep 30Trial updateAlaunos Therapeutics, Inc.doxorubicin
Alaunos closes registered direct offering, gross proceeds about $1.12 millionSep 22FinancingAlaunos Therapeutics, Inc.